Skip to main content

Table 1 mRNA-LNP delivery in cancer types

From: Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects

LNP name

mRNA

Cancer type

Pharmacological effects and feedback

Refs.

Cationic LNP

OVA and the control EGFP mRNA

Lymphoma

Significant increase in expression of CD80 and CD86 in the splenic CD11+ T-lymphocytes

Increased CD69+ T-cells of the spleen and the lymph nodes was the other sign of activation of T-cell responses

[174]

Ionizable lipid-based NPs (OF-Deg-Lin)

Human factor VIII (hFVIII) mRNA

Successful induction of protein expression and production in the B-cells of the spleen

[184]

LNP

IL-12A mRNA

Hepatocellular carcinoma

Enhancement of activated CD44+ immune cells such as CD3+ and CD4+ Th cells following IL-12 expression, shrinkage of tumor size, and increased survival in mice

[185]

cKK-E12 LNP

in vitro-transcribed mRNA was designed and formulated by cKK-E12 LNP to produce trastuzumab, an anti-HER2 monoclonal antibody

Breast cancer

In vivo PK characteristics of trastuzumab mRNA vs. synthetic trastuzumab (Herceptin®) in C57BL/6 mice: the significant higher serum level of trastuzumab, and interestingly the used dosage of this system was lower than Herceptin®, the higher morbidity-free survival in HER2+ mice and the lower average tumor volume via trastuzumab mRNA

[180]

PEG-coated hybrid of a cationic lipid-like compound (G0-C14) and poly lactic-co-glycolic acid (PLGA)

PTEN mRNA

Prostate cancer

Decrease in tumor size and weight with the least adverse effects on body weight increased apoptosis and declined survival of tumor cells

[36]